OncoResearch Lerchenfeld GmbH — Clinical Trial Site

13 Registered trials

6 Currently recruiting

Organisation

OncoResearch Lerchenfeld GmbH

Location

Hamburg, Germany

Identifier

ORG-100043447

Address

Lerchenfeld 14, Uhlenhorst, 22081, Germany

Departments

Hämatologie/Onkologie
N/A
OncoResearch Lerchenfeld
OncoResearch Lerchenfeld GmbH
Onkologie
Onkologie Lerchenfeld
Onkologischer Schwerpkt. Lerchenfeld
Praxis

Clinical trials at this site (13)

Search interface

A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS… Recruiting

2022-500479-29-00 International Prognostic Scoring System-Revised (IPSS-R 10 2023-03-28
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting

2022-502276-23-00 JAK2V617F-positive high-risk Polycythemia Vera 5 2024-04-25
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting

2022-501808-96-00 Mantle Cell Lymphoma 4 2023-05-15
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
A Phase 3 Study of Rusfertide (PTG-300) in Patients with Polycythemia Vera Ended

2023-509750-58-00 Polycythemia Vera 5 2022-09-21
A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS p… Ended

2024-516438-36-00 Patients with very low, low or intermediate risk myelod 4 2022-09-13
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Ended

2024-514775-17-00 Malignant B-cell lymphoma 4 2021-02-10
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended

2024-511929-60-00 Waldenström’s Macroglobulinemia 4 2021-01-28
CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients Ended

2023-507002-14-00 treatment-naïve or relapsed/refractory chronic lymphocy 4 2021-05-20
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15